Table 3.

Summary of additional hematological measurements during management of the acute BTH event with intensive pegcetacoplan treatment

Hematological parameters	Prior to event∗	At day 1	At day 2	At day 7-12†	At day 14-19†
Mean (SD) standardized values
Absolute reticulocyte count, 109 cells/L (normal reference range, 30-120)	107.5 (30.8) n = 12	140.7 (41.9) n = 9	138.0 (35.2) n = 10	137.3 (43.8) n = 11	136.4 (36.7) n = 11
Indirect bilirubin, μmol/L (normal reference range, 1.7-15.4)	12.5 (5.0) n = 13	30.3 (19.1) n = 11	16.7 (8.6) n = 11	9.7 (4.7) n = 12	11.1 (5.1) n = 11
Direct bilirubin, μmol/L (normal reference range, 0.0-3.4)	3.3 (1.5) n = 13	4.8 (1.9) n = 11	4.0 (1.9) n = 11	2.8 (1.7) n = 12	2.9 (1.5) n = 11
Platelets, 109 cells/L (normal reference range, 140-400)	143.9 (92.7) n = 13	152.2 (97.7) n = 10	147.0 (88.3) n = 11	143.9 (71.0) n = 12	150.6 (83.8) n = 12

In cases of repeat acute BTH events, the data relate to first acute BTH event. All local laboratory values were standardized to central laboratory based on normal ranges from respective laboratories. BTH, breakthrough hemolysis; RBC, red blood cell; SD, standard deviation.

^∗Most recent available measurement before intensive pegcetacoplan treatment.

^†Dependent on available measurement 7-12 days and 14-19 days after intensive pegcetacoplan treatment, respectively.